University of North Carolina at Chapel Hill

Professor

Dr. Liu is a leading expert in heparan sulfate biosynthesis and chemoenzymatic synthesis of heparin sulfate oligosaccharides. We are actively collaborating with Dr. Liu on multiple projects and currently sharing an NHLBI R01 grant with Dr. Liu. 

National Institute of Environmental Health Sciences

Director of X-ray Crystallography Facility 

Dr. Petersen is a highly prolific crystallographer with strong interest in heparan sulfate biosynthesis and HS-binding proteins. He has been a collaborator of Dr. Xu since 2004. Together we have solved 4 crystal structures and we are currently pursuing co-crystal structures of several HS-binding proteins (with HS oligosaccharide). 

Rensselaer Polytechnic Institute 

Professor

Dr. Wang is an expert in NMR spectrometry and has a strong interest in the role of HS in Alzheimer’s disease. We have been collaborating with Dr. Wang since 2018 using NMR to investigate the structural details of the interactions between HS and HS-binding proteins. 

University of Colorado Denver

Anschutz Medical Campus

Professor

Dr. Schmidt is a Pulmonary/Critical Care physician-scientist at University of Colorado Denver with expertise in acute respiratory distress syndrome (ARDS) and Sepsis. Dr. Schmidt has a long-standing interest in the role of heparan sulfate in ARDS/Sepsis. Together we are investigating the role of HS–RAGE interaction in ARDS and sepsis. 

Rensselaer Polytechnic Institute 

Professor

Dr. Linhardt is a leading expert on heparan sulfate structure and heparan sulfate binding proteins.  Dr. Xu has been collaborating with Dr. Linhardt group since 2005. We continue collaborating on structural analysis of HS and binding studies of HS-binding proteins. 

UC San Diego 

Professor

Dr. Varki is a one of the world leaders in Glycobiology who's lab focuses on understanding the biological functions of Sialic Acid.  We have shared interests in understanding how HMGB1 interacts with different classes of glycans under pathological conditions and have been collaboration since 2017. 

Manhattan Biosolutions

CEO

Dr. Shah is an expert in mAb therapeutics and founded Manhattan Biosolutions to discovery novel immunotherapy to treat cancer and inflammations. We have been working closely to further develop our anti-RAGE mAb. 

University at Buffalo 

Associate Professor

Dr. Shah is an expert in mAb therapeutics. We have been collaborating with Dr. Shah since 2019 to jointly develop anti-RAGE mAb